ebastine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seo, J | 1 |
| Park, M | 1 |
| Ko, D | 1 |
| Kim, S | 1 |
| Park, JM | 1 |
| Park, S | 1 |
| Nam, KD | 1 |
| Farrand, L | 1 |
| Yang, J | 1 |
| Seok, C | 1 |
| Jung, E | 1 |
| Kim, YJ | 1 |
| Kim, JY | 1 |
| Seo, JH | 1 |
1 other study available for ebastine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase.
Topics: Cell Line, Tumor; Cell Proliferation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mitogen-Activ | 2023 |